Annelieke R. Müller

Annelieke R. Müller

Auto-generated profile, based on publicly available information

Annelieke R. Müller

Amsterdam UMC, Emma Center for Personalized Medicine, Amsterdam, The Netherlands; Department of Pediatrics, Emma Children's Hospital, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands; United for Metabolic Diseases, The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2021 in Neurology
Verified
Journal Article
Open access
PDF file
AMAnnelieke R. Müller
Annelieke R. Müller
MBMarion M.M.G. Brands
Marion M.M.G. Brands
PVPeter M. van de Ven
Peter M. van de Ven
KRKit C.B. Roes
Kit C.B. Roes
Martina C CornelMartina C Cornel
Martina C Cornel
AEAgnies M. Van Eeghen
Agnies M. Van Eeghen
Objective To improve the use of N-of-1 studies in rare genetic neurodevelopmental disorders, we systematically reviewed the literature and formulated recommendations for future studies. Methods The systematic review protocol was registered in the PROSPERO International Prospective Register of Systematic Reviews (CRD42020154720). EMBASE and MEDLINE were searched for relevant studies. Information was recorded on types of interventions, outcome measures, validity, strengths, and limitations using standard reporting guidelines and critical appraisal tools. Qualitative and descriptive analyses were performed. Results Twelve studies met the N-of-1 inclusion criteria, including both single trials and series. Interventions were mainly directed to neuropsychiatric manifestations. Main strengths were the use of personalized and clinically relevant outcomes in most studies. Generalizability was compromised due to limited use of validated and generalizable outcome measures. Conclusion N-of-1 studies are sporadically reported in rare genetic neurodevelopmental disorders. Properly executed N-of-1 studies may provide a powerful alternative to larger randomized controlled trials in rare disorders and a much needed bridge between practice and science. We provide recommendations for future N-of-1 studies in rare genetic neurodevelopmental disorders, ultimately optimizing evidence-based and personalized care.

31 October 2022 in Movement Disorders Clinical Practice
Verified
Journal Article
Open access
ESEmma N.M.M. von Scheibler
Emma N.M.M. von Scheibler
AEAgnies M. Van Eeghen
Agnies M. Van Eeghen
TKTom J. de Koning
Tom J. de Koning
MKMark L. Kuijf
Mark L. Kuijf
JZJanneke R. Zinkstok
Janneke R. Zinkstok
EBErik Boot
Erik Boot
Background: With advances in clinical genetic testing, associations between genetic neurodevelopmental disorders and parkinsonism are increasingly recognized. In this review, we aimed to provide a comprehensive overview of reports on parkinsonism in genetic neurodevelopmental disorders and summarize findings related to genetic diagnosis, clinical features and proposed disease mechanisms.Methods: A systematic literature review was conducted in PubMed and Embase on June 15, 2021. Search terms for parkinsonism and genetic neurodevelopmental disorders, using generic terms and the Human Phenotype Ontology, were combined. Study characteristics and descriptive data were extracted from the articles using a modified version of the Cochrane Consumers and Communication Review Group's data extraction template. The protocol was registered in PROSPERO (CRD42020191035).Results: The literature search yielded 208 reports for data‐extraction, describing 69 genetic disorders in 422 patients. The five most reported from most to least frequent were: 22q11.2 deletion syndrome, beta‐propeller protein‐associated neurodegeneration, Down syndrome, cerebrotendinous xanthomatosis, and Rett syndrome. Notable findings were an almost equal male to female ratio, an early median age of motor onset (26 years old) and rigidity being more common than rest tremor. Results of dopaminergic imaging and response to antiparkinsonian medication often supported the neurodegenerative nature of parkinsonism. Moreover, neuropathology results showed neuronal loss in the majority of cases. Proposed disease mechanisms included aberrant mitochondrial function and disruptions in neurotransmitter metabolism, endosomal trafficking, and the autophagic‐lysosomal and ubiquitin‐proteasome system.Conclusion: Parkinsonism has been reported in many GNDs. Findings from this study may provide clues for further research and improve management of patients with GNDs and/or parkinsonism.

7 January 2025 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Open access
BHBibiche Den Hollander
Bibiche Den Hollander
EKEva M. M. Hoytema van Konijnenburg
Eva M. M. Hoytema van Konijnenburg
BHBrittany Hewitson
Brittany Hewitson
JMJan C. van der Meijden
Jan C. van der Meijden
BBBerith M. Balfoort
Berith M. Balfoort
CKClara D. van Karnebeek
Clara D. van Karnebeek
Inborn errors of metabolism (IEMs) are rare genetic conditions with significant morbidity and mortality. Technological advances have increased therapeutic options, making it challenging to remain up to date. A centralized therapy knowledgebase is needed for early diagnosis and targeted treatment. This study aimed to identify all treatable IEMs through a scoping literature review, followed by data extraction and analysis according to the Treatabolome principles. Knowledge of treatable IEMs, therapeutic categories, efficacy, and evidence was integrated into the Inborn Errors of Metabolism Knowledgebase (IEMbase), an online database encompassing all IEMs. The study identified 275 treatable IEMs, 18% of all currently known 1564 IEMs, according to the International Classification of Inherited Metabolic Disorders. Disorders of fatty acid and ketone body metabolism had the highest treatability (67%), followed by disorders of vitamin and cofactor metabolism (60%), and disorders of lipoprotein metabolism (42%). The most common treatment strategies were pharmacological therapy (34%), nutritional therapy (34%), and vitamin and trace element supplementation (12%). Treatment effects were most commonly observed in nervous system abnormalities (34%), metabolism/homeostasis abnormalities (33%), and growth (7%). Predominant evidence sources included case reports with evidence levels 4 (48%) and 5 (12%), and individual cohort studies with evidence level 2b (12%). Our study generated the Metabolic Treatabolome 2024. IEMs are the largest group of monogenic disorders amenable to disease‐modifying therapy. With drug repurposing efforts and advancements in gene therapies, this number will expand. IEMbase now provides up‐to‐date, comprehensive information on clinical and biochemical symptoms and therapeutic options, empowering patients, families, healthcare professionals, and researchers in improving patient outcomes.

1 January 2024 in Therapeutic Advances in Rare Disease
Verified
Journal Article
Open access
AMAnnelieke R. Müller
Annelieke R. Müller
NSNadia Y. van Silfhout
Nadia Y. van Silfhout
BHBibiche Den Hollander
Bibiche Den Hollander
DKDick H. C. Kampman
Dick H. C. Kampman
LBLianne Bakkum
Lianne Bakkum
AEAgnies M. Van Eeghen
Agnies M. Van Eeghen
Background: Individuals with genetic neurodevelopmental disorders (GNDs) or intellectual disability (ID) are often affected by complex neuropsychiatric comorbidities. Targeted treatments are increasingly available, but due to the heterogeneity of these patient populations, choosing a key outcome and corresponding outcome measurement instrument remains challenging. Objectives: The aim of this scoping review was to describe the research on outcomes and instruments used in clinical trials in GNDs and ID. Eligibility criteria: Clinical trials in individuals with GNDs and ID for any intervention over the past 10 years were included in the review. Sources of evidence: MEDLINE, PsycINFO, and Cochrane CENTRAL were searched. Titles and abstracts were independently screened for eligibility with a subsample of 10% double-screening for interrater reliability. Data from full texts were independently reviewed. Discrepancies were discussed until consensus was reached. Charting methods: Information was recorded on patient populations, interventions, designs, outcomes, measurement instruments, and type of reporter when applicable. Qualitative and descriptive analyses were performed. Results: We included 312 studies reporting 91 different outcomes, with cognitive function most frequently measured (28%). Various outcome measurement instruments ( n = 457) were used, with 288 in only a single clinical trial. There were 18 genetic condition-specific instruments and 16 measures were designed ad-hoc for one particular trial. Types of report included proxy-report (39%), self-report (22%), clinician-report (16%), observer-report (6%), self-assisted report (1%), or unknown (16%). Conclusion: This scoping review of current practice reveals a myriad of outcomes and outcome measurement instruments for clinical trials in GNDs and ID. This complicates generalization, evidence synthesis, and evaluation. It underlines the need for consensus on suitability, validity, and relevancy of instruments, ultimately resulting in a core outcome set. A series of steps is proposed to move from the myriad of measures to a more unified approach.

4 January 2024 in Journal of Applied Research in Intellectual Disabilities
Verified
Journal Article
Open access
Lianne BakkumLianne Bakkum
Lianne Bakkum
CPCélinde Paalman
Célinde Paalman
AMAnnelieke Müller
Annelieke Müller
AEAgnies M. Van Eeghen
Agnies M. Van Eeghen
CSCarlo Schuengel
Carlo Schuengel
Background: Experience sampling may be useful for mental health research with people with intellectual disability, and evidence of the potential benefits is starting to emerge. This multiple‐method study identified potential avenues for tailoring this method to the needs of people with intellectual disability.Method: A scoping review was conducted. Five databases were searched for experience sampling studies involving people with intellectual disability. In addition, seven adults with an intellectual disability tested experience sampling apps with standardised questions about mental health and were interviewed about their experiences in semi‐structured interviews.Results: Seven studies were included in the scoping review. Two studies investigated acceptability and feasibility. In the interviews, participants reported on the acceptability, availability, and appropriateness of experience sampling applications.Conclusions: There are still important gaps in knowledge about acceptability, availability, and appropriateness of experience sampling for this population. Researchers are recommended to tailor experience sampling applications to the needs and interests of individual users.

1 October 2025 in Genetics in Medicine
Verified
Journal Article
Open access
AMAnnelieke R. Müller
Annelieke R. Müller
BHBibiche Den Hollander
Bibiche Den Hollander
AEAgnies M. Van Eeghen
Agnies M. Van Eeghen
PVPeter M. van de Ven
Peter M. van de Ven
Martina C CornelMartina C Cornel
Martina C Cornel
CKClara D. van Karnebeek
Clara D. van Karnebeek
Treatments often do not reach individuals affected with a rare disease because of several barriers. Legislation generally requires that therapies for rare diseases are tested and licensed according to the same rules as established for common diseases. However, conventional methods for evaluating treatment effectiveness are hampered by the small patient populations. Single-case experimental designs (SCEDs), including n-of-1 trials, may offer a solution. Advantages of SCEDs include the ability to study individualized treatment options, use of within-participant randomization to generate a high level of evidence, and guarantee that each individual receives treatment. Their individualized approach also has a positive impact on ensuring relevance of treatment approaches and outcomes for affected individuals. However, designing and performing SCEDs in rare diseases comes with specific challenges related to heterogeneity, selection of outcome measures, accessibility of therapy, development of study medication, treatment and trial adherence, regulation, reimbursement, and financial limitations. Here, the lessons learned from SCEDs in rare diseases are discussed, based on real-world experiences from the involved clinicians and researchers, and informal participants' comments collected during and after participation in a SCED. Following these experiences and a thorough evaluation by an expert group, a manual for conducting SCEDs has been developed. This manual is presented as a steppingstone toward robust evidence generation and better access to treatments for individuals with rare diseases.